MarketPulse
C

$CSTL

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Castle Biosciences, Inc.

Castle Biosciences' Melanoma Test Validates Risk Stratification in Landmark 912-Patient Study

Castle Biosciences' DecisionDx-Melanoma test confirmed 2.6% nodal positivity in 912 patients predicted low-risk, supporting safe SLNB avoidance and validating the diagnostic platform.
CSTLgene expression profileprecision oncology
GlobeNewswire Inc.GlobeNewswire Inc.··Castle Biosciences, Inc.

Castle Biosciences Test Predicts JAK Inhibitor Response in Atopic Dermatitis

Castle Biosciences' AdvanceAD-Tx test predicts which atopic dermatitis patients will respond to JAK inhibitors, showing 5.5x better outcomes for identified responders versus alternative treatments.
CSTLpersonalized medicineatopic dermatitis